PL430675A1 - Bromocriptine for the treatment of ocular diseases related to elevated levels of vascular endothelial growth factor (VEGF) and a pharmaceutical composition containing bromocriptine - Google Patents

Bromocriptine for the treatment of ocular diseases related to elevated levels of vascular endothelial growth factor (VEGF) and a pharmaceutical composition containing bromocriptine

Info

Publication number
PL430675A1
PL430675A1 PL430675A PL43067519A PL430675A1 PL 430675 A1 PL430675 A1 PL 430675A1 PL 430675 A PL430675 A PL 430675A PL 43067519 A PL43067519 A PL 43067519A PL 430675 A1 PL430675 A1 PL 430675A1
Authority
PL
Poland
Prior art keywords
bromocriptine
vegf
treatment
growth factor
endothelial growth
Prior art date
Application number
PL430675A
Other languages
Polish (pl)
Inventor
Maciej OSĘKA
Anna Święch-Zubilewicz
Katarzyna Saładziak
Original Assignee
Osęka Maciej
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osęka Maciej filed Critical Osęka Maciej
Priority to PL430675A priority Critical patent/PL430675A1/en
Priority to PCT/IB2020/056885 priority patent/WO2021014372A1/en
Priority to EP20775397.1A priority patent/EP4003353A1/en
Publication of PL430675A1 publication Critical patent/PL430675A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Przedmiotem zgłoszenia jest bromokryptyna do zastosowania w leczeniu chorób oczu związanych z podwyższonym poziomem śródbłonkowego czynnika wzrostu naczyń (VEGF) zwiększoną przepuszczalnością naczyń krwionośnych i procesami nieprawidłowej angiogenezy. Zgłoszenie dotyczy także kompozycji farmaceutycznej do zastosowania w leczeniu chorób oczu związanych z podwyższonym poziomem śródbłonkowego czynnika wzrostu naczyń (VEGF) powstawania nieprawidłowej angiogenezy, charakteryzującej się tym, że zawiera bromokryptynę i dopuszczalny farmaceutycznie nośnik.The subject of this application is bromocriptine for use in the treatment of eye diseases associated with elevated levels of vascular endothelial growth factor (VEGF), increased vascular permeability and abnormal angiogenesis processes. The application also relates to a pharmaceutical composition for use in the treatment of eye diseases associated with elevated levels of vascular endothelial growth factor (VEGF) and the formation of abnormal angiogenesis, characterized in that it comprises bromocriptine and a pharmaceutically acceptable carrier.

PL430675A 2019-07-23 2019-07-23 Bromocriptine for the treatment of ocular diseases related to elevated levels of vascular endothelial growth factor (VEGF) and a pharmaceutical composition containing bromocriptine PL430675A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL430675A PL430675A1 (en) 2019-07-23 2019-07-23 Bromocriptine for the treatment of ocular diseases related to elevated levels of vascular endothelial growth factor (VEGF) and a pharmaceutical composition containing bromocriptine
PCT/IB2020/056885 WO2021014372A1 (en) 2019-07-23 2020-07-22 Bromocriptine for use in treating eye diseases associated with elevated level of vegf and a pharmaceutical composition comprising bromocriptine
EP20775397.1A EP4003353A1 (en) 2019-07-23 2020-07-22 Bromocriptine for use in treating eye diseases associated with elevated level of vegf and a pharmaceutical composition comprising bromocriptine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL430675A PL430675A1 (en) 2019-07-23 2019-07-23 Bromocriptine for the treatment of ocular diseases related to elevated levels of vascular endothelial growth factor (VEGF) and a pharmaceutical composition containing bromocriptine

Publications (1)

Publication Number Publication Date
PL430675A1 true PL430675A1 (en) 2021-01-25

Family

ID=74193941

Family Applications (1)

Application Number Title Priority Date Filing Date
PL430675A PL430675A1 (en) 2019-07-23 2019-07-23 Bromocriptine for the treatment of ocular diseases related to elevated levels of vascular endothelial growth factor (VEGF) and a pharmaceutical composition containing bromocriptine

Country Status (3)

Country Link
EP (1) EP4003353A1 (en)
PL (1) PL430675A1 (en)
WO (1) WO2021014372A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8426922D0 (en) * 1984-10-24 1984-11-28 Sandoz Ltd Galenic formulation
WO2004103262A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
AU2016206366B2 (en) * 2008-01-14 2017-03-02 Veroscience, Llc Parenteral formulations of dopamine agonists
CA2727297A1 (en) * 2008-06-09 2009-12-17 Boehringer Ingelheim International Gmbh New emulsions for producing medicinal products
PL232974B1 (en) * 2015-12-09 2019-08-30 Ofta Spolka Z Ograniczona Odpowiedzialnoscia Application of the dopaminergic receptors type 2 agonists in treatment of eye chronic diseases caused by the increased level of endothelium derivative cell growth factor

Also Published As

Publication number Publication date
EP4003353A1 (en) 2022-06-01
WO2021014372A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
PH12020551839A1 (en) High concentration vegf receptor fusion protein containing formulations
PH12019500423A1 (en) Pharmaceutical composition
MX2020001403A (en) Quinoline derivatives for treating infections with helminths.
MXPA05006038A (en) Pharmacological vitreolysis.
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
MX2019013799A (en) Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient.
EA201790889A1 (en) OPHALMOLOGICAL SOLUTION
PH12020551786A1 (en) Combination treatment for eye fibrosis and/or angiogenesis
MX2021014575A (en) Fused heterocyclic derivatives.
MX2020004730A (en) Sustained-release implants for lowering intraocular pressure with extended duration of effect.
RU2014140797A (en) METHOD FOR TREATING A HIGH DEGREE KERATOCONUS AND MYOPIA WITH A THIN CORNEA
MX2021002322A (en) Novel methods.
EA202191684A1 (en) DRUG CONTAINING URSODEOXYCHOLIC ACID FOR TREATMENT OR PREVENTION OF PRESBIOPIA
MX338323B (en) Topical ophthalmic peptide formulation.
DE602005020178D1 (en) 5,6,7-TRIHYDROXYPHEPTANIC ACIDS AND ANALOGS FOR THE TREATMENT OF EYE DISEASES AND DISEASES ASSOCIATED WITH HYPERPROLIFERATIVES AND ANGIOGENIC REACTIONS
PL430675A1 (en) Bromocriptine for the treatment of ocular diseases related to elevated levels of vascular endothelial growth factor (VEGF) and a pharmaceutical composition containing bromocriptine
MX2020011536A (en) Liquid depot for non-invasive sustained delivery of agents to the eye.
PL424452A1 (en) Inhibitors of inactive endopeptidase (NEP) and human soluble endopeptidase (hSEP) for prevention and treatment of eye diseases
MX2020011535A (en) Eye drop formulation and method for sustained delivery of medicament to the retina.
PH12021550372A1 (en) The use of alpha-2-adrenergic receptor agonists for improving vision
EA202192183A1 (en) COMPOSITIONS WITH LIPOFUSCIN REMOVAL ACTIVITY FROM RETINA CELLS
MX2022000468A (en) Methods for alleviating pterygium-associated worry about eye appearance.
EP4338751A3 (en) Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
MX2019007485A (en) Ophtalmologic preparation.
EA202091523A1 (en) THERAPEUTIC AGENT FOR GLAUKOMA TREATMENT CONTAINING FP-RECEPTOR AGONIST AND -BLOCKER